SCHEMBL207136

SCHEMBL207136

CN(C)C1(Cc2cccc(Cl)c2)CCC(NC(=O)CCC(=O)NCc2cc(F)cc(C(F)(F)F)c2)CC1

nearest known ligand 0.45

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
SMYD3 Q9H7B4 1/20 0.42
CCR2 P41597 5/20 0.42
SIGMAR1 Q99720 2/20 0.40
CYP3A4 P08684 3/20 0.39
LMNA P02545 1/20 0.39
THRB P10828 1/20 0.39
HPGD P15428 1/20 0.39
EPHX2 P34913 2/20 0.39
CETP P11597 1/20 0.39
MAPK1 P28482 1/20 0.38
UBE2M P61081 1/20 0.38
DCUN1D1 Q96GG9 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL206014 0.93 SIGMAR1 (0.43) SIGMAR1CYP3A4LMNATHRBHPGD
SCHEMBL205370 0.87 SIGMAR1 (0.50) SIGMAR1LMNATHRBHPGDEPHX2
SCHEMBL206772 0.87 EPHX2 (0.47) SIGMAR1CYP3A4THRBHPGDEPHX2
SCHEMBL208642 0.86 EPHX2 (0.45) SMYD3SIGMAR1THRBHPGDEPHX2
SCHEMBL208415 0.85 SMYD3 (0.47) SMYD3CCR2SIGMAR1THRBHPGD
SCHEMBL206617 0.85 SIGMAR1 (0.43) SIGMAR1CYP3A4THRBHPGDEPHX2
SCHEMBL206620 0.84 EPHX2 (0.46) SIGMAR1LMNATHRBHPGDEPHX2
SCHEMBL208251 0.84 SIGMAR1 (0.42) SIGMAR1CYP3A4THRBHPGDEPHX2
SCHEMBL207581 0.83 POLB (0.46) SIGMAR1CYP3A4THRBHPGDEPHX2
SCHEMBL206406 0.83 EPHX1 (0.42) SIGMAR1LMNAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088763-B2 e.g. N-[1-(2,6-dichloro-benzyl)-pyrrolidin-3-yl]-N'-[4-dimethylamino-4-(4-methyl-benzyl)-cyclohexyl]-succinamide; noradrenaline and serotonin reuptake ihibitor; opioid ORL-1 receptor ligand; analgesic, antidepressant, anxiolytic agent, neurodegenerative diseases GRUENENTHAL GMBH (DE) 2012-01-03 US claimed
EP-1745010-B1 SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES GRUENENTHAL GMBH (DE) 2009-08-05 EP claimed
US-20070112007-A1 Cyclohexyl-1, 4-diamine compounds GRUENENTHAL GMBH (DE) 2007-05-17 US claimed
US-8088763-B2 e.g. N-[1-(2,6-dichloro-benzyl)-pyrrolidin-3-yl]-N'-[4-dimethylamino-4-(4-methyl-benzyl)-cyclohexyl]-succinamide; noradrenaline and serotonin reuptake ihibitor; opioid ORL-1 receptor ligand; analgesic, antidepressant, anxiolytic agent, neurodegenerative diseases GRUENENTHAL GMBH (DE) 2012-01-03 US disclosed
EP-1745010-B1 SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES GRUENENTHAL GMBH (DE) 2009-08-05 EP disclosed
US-20070112007-A1 Cyclohexyl-1, 4-diamine compounds GRUENENTHAL GMBH (DE) 2007-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070112007-A1 Cyclohexyl-1, 4-diamine compounds PKD1, DDC, DPYD SMYD3 3967/4885CCR2 2965/4885SIGMAR1 3262/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.